Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.56 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28272571 | 0.92 | P2RY2 (0.68) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL4316734 | 0.91 | P2RY2 (0.64) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL8399705 | 0.89 | P2RY2 (0.58) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL6402546 | 0.89 | TSHR (0.65) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL8399850 | 0.89 | P2RY2 (0.58) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL20992890 | 0.89 | P2RY2 (0.74) | P2RY2TSHRGLALMNATHRB | |
| Cytarabine 5'-Phosphate SCHEMBL28968855 | 0.87 | P2RY2 (0.69) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL14125515 | 0.87 | P2RY2 (0.62) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL39904 | 0.86 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 | |
| SCHEMBL532547 | 0.86 | P2RY2 (0.76) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5872108-A | Reduction of infarct volume using citicoline | INTERNEURON PHARMACEUTICALS, INC. (US) | 1999-02-16 | — | — | US | claimed |
| US-5827832-A | Method of protecting brain tissue from cerebral infarction subsequent to ischemia | INTERNEURON PHARMACEUTICALS, INC. (US) | 1998-10-27 | — | — | US | claimed |
| US-5801160-A | Method of protecting brain tissue from cerebral infarction subsequent to ischemia | INTERNEURON PHARMACEUTICALS, INC. (US) | 1998-09-01 | — | — | US | claimed |
| US-4386078-A | CYTIDINE DIPHOSPHOETHANOLAMINES AND CYTIDINEDIPHOSPHOCHOLINE; STROKE, CARDIOVASCULAR DISEASE, INJURIES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1983-05-31 | — | — | US | claimed |
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-06-15 | — | — | US | disclosed |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | METANOI THERAPEUTICS INC (US) | 2023-06-08 | — | — | US | disclosed |
| EP-2618832-B1 | COMPOSITION COMPRISING SOD, LUTEIN AND ZEAXANTHIN | OMNIVISION GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11607421-B2 | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof | METANOI THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4132490-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | Metanoi Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3965820-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY | The Regents of the University of California (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3847257-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | Ospedale San Raffaele S.r.l. (IT) | 2021-07-14 | — | — | EP | disclosed |
| EP-1379657-A2 | DISEASE-ASSOCIATED PROTEIN | Novartis AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20020161220-A1 | Tetraphosphonate bicyclic trisanhydrides | GILEAD PHARMASSET LLC | 2002-10-31 | — | — | US | disclosed |
| WO-2002081513-A2 | DISEASE-ASSOCIATED PROTEIN | NOVARTIS AG (CH) | 2002-10-17 | — | — | WO | disclosed |
| US-6326490-B1 | ANTIPROLIFERATION AGENTS OR ANTICARCINOGENIC AGENTS | PHARMASSET, LTD. | 2001-12-04 | — | — | US | disclosed |
| EP-0934325-A4 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | PHARMASSET LTD (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-0934325-A1 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | Pharmasset, Ltd. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015563-A1 | TETRAPHOSPHONATE BICYCLIC TRISANHYDRIDES | PHARMASSET, LTD. (US) | 1998-04-16 | — | — | WO | disclosed |
| US-4386078-A | CYTIDINE DIPHOSPHOETHANOLAMINES AND CYTIDINEDIPHOSPHOCHOLINE; STROKE, CARDIOVASCULAR DISEASE, INJURIES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1983-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | PHOSPHO1, EGLN3, HIF1AN | P2RY2 2371/4885TSHR 2306/4885GLA 4071/4885 |
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, GLS, GLS2 | P2RY2 4005/4885TSHR 4100/4885GLA 1579/4885 |
| US-11607421-B2 | Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof | PHOSPHO1, SGMS2, CHKB | P2RY2 4503/4885TSHR 4376/4885GLA 2852/4885 |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | P2RY2 4503/4885TSHR 4376/4885GLA 2852/4885 |
| US-20020161220-A1 | Tetraphosphonate bicyclic trisanhydrides | IDH1, PPIP5K2, DHPS | P2RY2 3110/4885TSHR 4045/4885GLA 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.